Print Email

2013 MASCC/ISOO Annual Meeting Study Group Workshops

Past Workshops:  2016  |   2015  |  2014  |  2013  |  2012  |  2011

Mucositis Research
Chair: R. Lalla

This workshop, presented by the Mucositis Study Group, included both basic research and clinical perspectives on Session 1 focused on the effects and treatment of mucositis in animal models, while Session 2 addressed the prevention and treatment of mucositis in head and neck cancer patients, breast cancer patients, pediatric patients, and hematopoietic stem cell transplant recipients.

Session 1: Pre-clinical Studies 
Chair: Richard Logan 

  • Ker Y. Cheah, Gordon S. Howarth, Keren A. Bindon, James A. Kennedy, and Susan E. P. Bastian (Australia and USA). Grape Seed Procyanidin Fractions Enhance the Impact of 5-Fluorouracil Chemotherapy on Colon Cancer Cells.
  • Abdul Rahman Al-Azri, Rachel Gibson, Joanne Bowen, Andrea Stringer, Dorothy Keefe, Richard Logan (Australia and Oman). Expression of Matrix Metalloproteinase -2 and Tissue Inhibitor of Metalloproteinase-1 in Oral Mucositis Following Irinotecan Chemotherapy.
  • E Bateman, C Wilson, C Keefe, J Bowen, A Wignall, E Plews and D Keefe (Australia) . Fractionated Radiotherapy in a Rat Model Causes Dose-Dependent Changes in Collagen Deposition, and Expression of Transforming Growth factor β1, Smad3 and Smooth Muscle Actin α1F.
  • Biasotto Matteo, Ottaviani Giulia, Gobbo Margherita, Amadori Francesca, Schumacher Richard Fabian, Majorana Alessandra (Italy). Low Level Laser Therapy in 5-FU-Induced Oral Mucositis in Mice.
  • B. Mayo, E. Bateman, A. Stringer, E. Plews, K. Pishas, C. Pietra, S. Cantoreggi and D. Keefe (Australia and Switzerland). The Effect of the New Selective GLP-2 Agonist, Elsiglutide, on Irinotecan-Induced Diarrhoea and Mucositis in the Rat.
  • Suzanne M Abimosleh, Cuong D Tran and Gordon S Howarth (Australia). Emu Oil Expedites Small Intestinal Repair Following 5-Fluorouracil-Induced Mucositis in Rats.

Session 2: Clinical Studies
Chair: Stephen Sonis

  • Bossi P, Russi E, Numico G, Mazzer M, Saibene G. (Italy), Mucositis Prevention and Treatment in Head and Neck Cancer Patients Treated with (Chemo)radiation: Report of an Italian Survey.
  • J. Bos-den Braber, C.M.J. Potting, E.M. Bronkhorst, M.C.D.N.J.M. Huysmans, N.M.A. Blijlevens. (The Netherlands). Dental Care and Oral Complaints of Hematopoietic Stem Cell Transplant Patients: A Survey. 
  • Biasotto Matteo, Gobbo Margherita, Ottaviani Giulia, Amadori Francesca, Conti Giulio, Majorana Alessandra (Italy). High-Level Laser tTherapy in the Treatment of Chemotherapy-Induced Oral Mucositis in Paediatric Patients.
  • Alexandra H.E. Herbers, Anton F.J. de Haan, Walter J.F.M. van der Velden, J.Peter Donnelly and Nicole M.A. Blijlevens (The Netherlands). Relationship Between Intestinal Mucositis, Neutropenia and Bacteraemia Among Hematopoietic Stem Cell Transplant Recipients.
  • R.R. Allison, A.A. Ambrad, Y.M. Arshoun, R. Carmel, D.F. Ciuba, E. Feldman, S.E. Finkelstein, R.B. Gandhavadi, D.E. Heron, S.C. Lane, J.M. Longo, C.J. Meakin, D. Papadopoulos, D.E. Pruitt, L.M. Steinbrenner, M.A. Taylor, W.M. Wisbeck, G.E. Yuh, D.P. Nowotnik, S.T. Sonis (USA). Results from the Multi-Institutional, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy of Mugardtm in Mitigating Oral Mucositis in Chemoradiation-Treated Head and Neck Cancer Patients.
  • Ourania Nicolatou-Galitis, Adamantia Nikolaidi, Ilias Athanassiadis, Erofili Papadopoulou, Stephen Sonis (Greece and USA). Oral Ulcers in Patients with Advanced Breast Cancer Receiving Everolimus: A Case Series Report on Clinical Presentation and Management.

Expert Panel Discussion

  • Gordon Howarth, Richard Logan, Stephen Sonis. Mapping the next 5 years in mucositis research: Breakthroughs and disruptive technology. 
  • Moderators: Joanne Bowen and Sharon Elad, Workshop Co-Chairs 

Improving Adherence in Elderly Receiving Oral Agents for Cancer Treatment
Chair: Manon Lemonde

This workshop, presented by the Education Study Group, addressed the difficulty of educating elderly cancer patients about adherence issues. It included topics of patient competence as a factor in adherence and safety, clinical challenges with respect to physiological, psychological, and cognitive factors, and the use of MASCC’s Oral Agent Teaching Tool© with the elderly.

  • Presenters: Walter Baumann, Sultan Kav, Massey Nematollahi, Paz Fernandez Ortega, Pongpak Pittayapan, Christoph Riese, Pablo Zamora
  • Discussants: Manon Lemonde, Judith Johnson, Cynthia Rittenberg

Targeted Therapy in the Elderly
Chair: C.B. Boers-Doets, Skin Toxicity Study Group
Co-Chair: Christopher Steer, Geriatrics Study Group

This workshop, presented jointly by the Geriatrics and the Skin Toxicity Study Groups, addressed the impact of targeted agents on older cancer patients, who are at increased risk for toxicities of such agents. Adverse effects include skin problems, periodontal disease, neuropathy, and cardiac conditions.

Session 1

  • Christopher Steer (Australia). Introduction.
  • Christine B. Boers-Doets. Literature Review: Studies Performed Focusing Upon Elderly Populations & Targeted Therapy Interventions.
  • Ulrich Wedding (Germany). Comprehensive Geriatric Assessment (CGA): Performing a CGA and Utilizing Its Results As a Guide for Treatment Plan Decision-Making.
  • Holly M. Holmes (USA). Practical Use of Geriatric Assessment in the Older Patient Receiving Targeted Anticancer Therapy.
  • Edward T.H. Yeh (USA). Oncolo-Cardiology and its Future Role in Improving the Care of the Cancer Patient.
  • Michael S. Ewer (USA). The Changing Role of Anthracycline Cardiotoxicity: Where We Were and What We Have Learned.

Session 2

  • Jean Bernard Durand (USA). Assessment of the Cancer Patient with Cardiovascular Disease-Don’t Kill The Heart Along With the Tumor.
  • Mario E. Lacouture (USA). Special Attention to Dermatological Adverse Events in Older Adult Cancer Patients.
  • Joel B. Epstein (USA). Special Attention to Mucosal Adverse Events in Older Adult Cancer Patients.

Conclusion

  • Christopher Steer (Australia). Targeted Therapy and the Delivery of “Best Practice” Supportive Care for the Older Adult Cancer Patient: The Attendees' Perspective.

Emerging Drug Resistance in Febrile Neutropenia Management: A Global Perspective
Chairs: Bernardo Rapoport and Jean Klastersky

This workshop, presented by the Neutropenia, Infection, and Myelosuppression Study Group, focused on mechanisms of drug resistance in febrile neutropenic patients. In addition to epidemiology in the USA and globally, topics included drug resistance in febrile neutropenic patients, including patients with fungal infections, patients with acute leukemia  and and hematopoietic stem cell recipients.

  • Bernardo L. Rapoport (South Africa). Introduction and Overview. 
  • Kenneth Rolston (USA). Mechanism of Resistance in Febrile Neutropenic Patients.
  • A.Freifeld (USA). Epidemiology BSI in Neutropenic Patients in the USA and Globally.
  • S. H. Zinner (USA). Drug Resistance in Gram Positive + Gram Negative Neutropenic Patient.
  • Thomas J. Walsh (USA). Drug Resistance in Neutropenic Patients with Fungal Infections.
  • M Aoun (Belgium). Drug Resistance in Infections in Acute Leukemia and Hematopoietic Stem Cell Transplant Neutropenic Patients.
  • Haralambos Raftopoulos (USA). Drug Resistance in Febrile Neutropenia in the USA.
  • Alex Chan (Singapore). Drug Resistance in Neutropenic Patients in Singapore.
  • Jean Klastersky (Belgium). Summary and Future Directions.

Cancer Cachexia and Fatigue in Advanced Cancer Patients
Chairs: Karin Olson and Florian Strasser

Cachexia and fatigue, though common in advanced cancer, are often under-recognized and poorly managed. This clinically oriented workshop, presented by the Fatigue Study Group and the Nutrition and Cachexia Study Group, focused on state-of-the-art information on the recognition, assessment, and management of these distinct, but overlapping, conditions. 

  • Karin Olson (Canada) and Florian Strasser (Switzerland). Current Definitions of Cancer Cachexia and Fatigue.
  • Florian Strasser. (Switzerland) Recognition of Cachexia and Fatigue in Routine Daily  Oncology Practice and Embedded in Cancer Clinical Trials.
  • Mellar Davis (USA). Mechanisms of Cachexia and Fatigue.
  • Ioannis Gioulbasanis (Greece). Prioritization and Assessment in Practices and Research.
  • Barbara Murphy (USA). Why Do Cachexia and Fatigue Matter in Clinical Oncology?
  • Line Oldervoll (Norway). Clinical Management of Cachexia and Fatigue: Physical Activity Interventions.
  • Liz Isenring (Australia). Clinical Management of Cachexia and Fatigue: Nutritional Interventions.
  • Jann Arends (Germany). Clinical Management of Cachexia and Fatigue: Pharmacological Treatments Including Anticancer Drugs.
  • Sriram Yennu (USA), Karin Olson (Canada), Sami Antoun (France). Case Studies.